Ebtehal M. Husseiny

492 total citations
23 papers, 398 citations indexed

About

Ebtehal M. Husseiny is a scholar working on Organic Chemistry, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Ebtehal M. Husseiny has authored 23 papers receiving a total of 398 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Organic Chemistry, 8 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Ebtehal M. Husseiny's work include Synthesis and biological activity (16 papers), Synthesis and Characterization of Heterocyclic Compounds (9 papers) and Click Chemistry and Applications (8 papers). Ebtehal M. Husseiny is often cited by papers focused on Synthesis and biological activity (16 papers), Synthesis and Characterization of Heterocyclic Compounds (9 papers) and Click Chemistry and Applications (8 papers). Ebtehal M. Husseiny collaborates with scholars based in Egypt, Saudi Arabia and Indonesia. Ebtehal M. Husseiny's co-authors include Hamada S. Abulkhair, Eman A. Fayed, Adel Ghiaty, Ashraf H. Bayoumi, Mona S. El‐Zoghbi, Ahmed A. Al‐Karmalawy, Aisha Y. Hassan, Kurls E. Anwer, Marwa T. Sarg and Magda M. F. Ismail and has published in prestigious journals such as Bioorganic & Medicinal Chemistry, New Journal of Chemistry and Bioorganic Chemistry.

In The Last Decade

Ebtehal M. Husseiny

21 papers receiving 392 citations

Peers

Countries citing papers authored by Ebtehal M. Husseiny

Since Specialization

Citations

This map shows the geographic impact of Ebtehal M. Husseiny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ebtehal M. Husseiny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ebtehal M. Husseiny more than expected).

Fields of papers citing papers by Ebtehal M. Husseiny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ebtehal M. Husseiny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ebtehal M. Husseiny. The network helps show where Ebtehal M. Husseiny may publish in the future.

Co-authorship network of co-authors of Ebtehal M. Husseiny

This figure shows the co-authorship network connecting the top 25 collaborators of Ebtehal M. Husseiny. A scholar is included among the top collaborators of Ebtehal M. Husseiny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ebtehal M. Husseiny. Ebtehal M. Husseiny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploring 1,2,3-triazole-Schiff’s base hybrids as innovative EGFR inhibitors for the treatment of breast cancer: In vitro and in silico study 2025 ·Bioorganic Chemistry ·(unknown), (unknown), Ebtehal M. Husseiny, (unknown), (unknown)	6
2	Comparative Study of Conventional, Grinding, and Microwave‐Assisted Synthesis of Aminopyrazolones and Diaminopyrazoles: Exploring the Antitumor Activity, Dual CDK‐2/CA IX Inhibition Potential, and Apoptosis Induction 2025 ·Drug Development Research ·Kurls E. Anwer, (unknown), (unknown), Najla Altwaijry, Ebtehal M. Husseiny	1
3	Comparison between conventional, grinding, and microwave synthesis of methylpyrazoles as VEGFR-2/HSP90 dual inhibitors 2025 ·Future Medicinal Chemistry ·Ebtehal M. Husseiny, (unknown), Najla Altwaijry, Asmaa Saleh, Kurls E. Anwer	0
4	New Imidazothiazine-containing Scaffolds as Promising Anticancer Agents: Design, Synthesis, and Antiproliferative Estimation 2025 ·(unknown), Marwa T. Sarg, (unknown), Ebtehal M. Husseiny	0
5	1,2,3-Triazole-Based Hybrids as EGFR Inhibitors: An overview 2025 ·(unknown), (unknown), Ebtehal M. Husseiny, Magda A.‐A. El‐Sayed, (unknown)	1
6	Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights 2024 ·Bioorganic Chemistry ·(unknown), Marwa T. Sarg, (unknown), Eman S. Nossier, Ebtehal M. Husseiny	10
7	Design, synthesis, and mechanistic insight of novel imidazolones as potential EGFR inhibitors and apoptosis inducers 2024 ·Bioorganic Chemistry ·(unknown), Hamada S. Abulkhair, (unknown), (unknown), Ebtehal M. Husseiny	13
8	In vivo evaluation of novel synthetic pyrazolones as CDK9 inhibitors with enhanced pharmacokinetic properties 2024 ·Future Medicinal Chemistry ·Ebtehal M. Husseiny, Hamada S. Abulkhair, (unknown), (unknown), Kurls E. Anwer	4
9	Novel Benzochromenes: Design, Synthesis, Cytotoxicity, Molecular Docking and Mechanistic Investigations 2024 ·Future Medicinal Chemistry ·(unknown), Hamada S. Abulkhair, (unknown), (unknown), Ahmed A. Al‐Karmalawy, Ebtehal M. Husseiny	6
10	Molecular overlay-guided design of new CDK2 inhibitor thiazepinopurines: Synthesis, anticancer, and mechanistic investigations 2023 ·Bioorganic Chemistry ·Ebtehal M. Husseiny, Hamada S. Abulkhair, Asmaa Saleh, Najla Altwaijry, (unknown), (unknown)	14
11	Exploring the cytotoxic effect and CDK-9 inhibition potential of novel sulfaguanidine-based azopyrazolidine-3,5-diones and 3,5-diaminoazopyrazoles 2023 ·Bioorganic Chemistry ·Ebtehal M. Husseiny, Hamada S. Abulkhair, (unknown), Kurls E. Anwer	29
12	Mimicry of sorafenib: novel diarylureas as VEGFR2 inhibitors and apoptosis inducers in breast cancer 2023 ·New Journal of Chemistry ·Magda M. F. Ismail, Ebtehal M. Husseiny, Mona H. Ibrahim	8
13	Aminopyridone-Linked Benzimidazoles: A Fragment-Based Drug Design for the Development of CDK9 Inhibitors 2023 ·Future Medicinal Chemistry ·Ebtehal M. Husseiny, Hamada S. Abulkhair, (unknown), (unknown), Mona S. El‐Zoghbi	10
14	Apoptosis induction, PARP-1 inhibition, and cell cycle analysis of leukemia cancer cells treated with novel synthetic 1,2,3-triazole-chalcone conjugates 2022 ·Bioorganic Chemistry ·(unknown), Eman A. Fayed, Ebtehal M. Husseiny, Hamada S. Abulkhair	57
15	The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia 2022 ·Bioorganic Chemistry ·(unknown), Eman A. Fayed, Ebtehal M. Husseiny, Hamada S. Abulkhair	45
16	Rationale design, synthesis, cytotoxicity evaluation, andin silicomechanistic studies of novel 1,2,3-triazoles with potential anticancer activity 2022 ·New Journal of Chemistry ·(unknown), Eman A. Fayed, Ebtehal M. Husseiny, Hamada S. Abulkhair	39
17	From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity 2021 ·Bioorganic & Medicinal Chemistry ·(unknown), Adel Ghiaty, Ashraf H. Bayoumi, Ahmed A. Al‐Karmalawy, Ebtehal M. Husseiny, Mona S. El‐Zoghbi, Hamada S. Abulkhair	66
18	Utility of 1,8-diaminonaphthalene in the synthesis of some novel heterocycles as potent anti-MRSA with dual DNA gyrase and topoisomerase IV inhibition 2021 ·Egyptian Journal of Chemistry ·Ebtehal M. Husseiny, (unknown), (unknown)	4
19	Synthesis, cytotoxicity of some pyrazoles and pyrazolo[1,5-a]pyrimidines bearing benzothiazole moiety and investigation of their mechanism of action 2020 ·Bioorganic Chemistry ·Ebtehal M. Husseiny	41
20	Synthesis and Anticancer Evaluation of Some Novel Thiophene, Thieno[3,2‐d]pyrimidine, Thieno[3,2‐b]pyridine, and Thieno[3,2‐e][1,4]oxazepine Derivatives Containing Benzothiazole Moiety 2019 ·Journal of Heterocyclic Chemistry ·Aisha Y. Hassan, Ebtehal M. Husseiny	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact